<SUBMISSION>
<ACCESSION-NUMBER>0001193125-04-122813
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20040722
<ITEMS>5
<ITEMS>7
<FILING-DATE>20040722
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>DAVITA INC
<CIK>0000927066
<ASSIGNED-SIC>8090
<IRS-NUMBER>510354549
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-14106
<FILM-NUMBER>04926709
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>601 HAWAII STREET
<CITY>EL SEGUNDO
<STATE>CA
<ZIP>90245
<PHONE>3105362400
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>601 HAWAII STREET
<CITY>EL SEGUNDO
<STATE>CA
<ZIP>90245
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>TOTAL RENAL CARE HOLDINGS INC
<DATE-CHANGED>19950524
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>TOTAL RENAL CARE INC
<DATE-CHANGED>19940719
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>Form 8-K </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%"
SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section 13 or 15(d) of the </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of Report (date of earliest event reported): July 22, 2004 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="6"><B>DAVITA INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="21%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1-4034</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>No. 51-0354549</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>601 Hawaii Street
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>El Segundo, California 90245 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>(Address of principal executive offices including Zip Code) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>(310) 536-2400 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Not applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000"
ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INFORMATION TO BE INCLUDED IN THE REPORT </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 5. Other Events and Regulation FD Disclosure. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Attached hereto as Exhibit 99.1 is a press release issued on July 22, 2004
announcing that DaVita Inc. entered into a definitive agreement to acquire Physicians Dialysis, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Item 7. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT><BR><HR WIDTH="44" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of DaVita Inc, dated July 22, 2004.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Note: The information contained in
this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be &#147;filed&#148; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
</I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">D<SMALL>A</SMALL>V<SMALL>ITA</SMALL> I<SMALL>NC</SMALL>.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Date: July 22, 2004</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/ L<SMALL>ORI</SMALL> S. R<SMALL>ICHARDSON</SMALL>-P<SMALL>ELLICIONI</SMALL></FONT></P><HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Lori S. Richardson-Pellicioni </B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>General Counsel and</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Secretary</B></FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT><BR><HR WIDTH="42" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P><HR WIDTH="61" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release, dated July 22, 2004.</FONT></TD></TR>
</TABLE>
</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g76900clip_image002.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Contact:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">LeAnne Zumwalt</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Investor Relations</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">DaVita Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">310 536-2420</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>DaVita to Acquire
Physicians Dialysis, Inc.</U> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">El Segundo, CA, July, 22, 2004 - DaVita Inc.
(NYSE: DVA), announced that it has entered into a definitive agreement to acquire Physicians Dialysis, Inc. (&#147;PDI&#148;), in a cash-for-stock merger transaction valued at approximately $150 million. The Company expects to close the transaction
by the end of the third quarter. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">DaVita&#146;s acquisition of PDI will add 24
dialysis centers to its operations and several acute services agreements, representing a total census of approximately 1,700 patients. This transaction strengthens DaVita&#146;s presence in the states of Michigan, Texas, Pennsylvania, Alabama, New
Jersey and West Virginia, while adding a new presence in two additional states, Connecticut and Massachusetts. PDI&#146;s current annualized revenue is approximately $75 million and current dialysis revenue per treatment is approximately $286. The
acquisition is anticipated to be EPS neutral in the first year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Completion of
the transaction is subject to customary closing conditions including the receipt of bank approval under the terms of DaVita&#146;s credit facility. The Company also intends to amend its credit facility and increase the term debt by $250 million in
order to fund ongoing acquisition activities and potential share repurchases over time. The Company has received Hart-Scott-Rodino antitrust clearance for this transaction. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Kent Thiry, Chairman and CEO of DaVita, commented, &#147;PDI is a leading regional company in our industry and represents an important
strengthening of our presence in several core markets.&#148; He added, &#147;The two companies share a common focus on quality and culture. The transaction fits with the Company&#146;s target strategies and is expected to provide longer-term market
synergies.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Mr. Thiry also said, &#147;We are looking forward to joining
the dedicated teammates and physicians associated with PDI in continuing to provide quality care to their ESRD patients and to expanding our relationships with PDI medical directors and the respected nephrologists in these communities.&#148;
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Patrick Ryan, Chairman and CEO of Physicians Dialysis, stated, &#147;This is
an important day for the company as all our team has worked hard together to build PDI. We share a common mission and culture with DaVita. The company, under Kent&#146;s leadership, will have the resources to continue to build upon our foundation,
while ensuring that our patients continue to receive superior quality care and our team members have outstanding opportunities for professional growth.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company will discuss further details of this transaction on its second quarter earnings conference call scheduled for Tuesday, August 3, 2004; at 12:00 pm EDT. The
dial in number for this call is 800 399-4406 and a web cast can be accessed at <U>www.davita.com</U>. Investors who are unable to listen to the DaVita conference call will be able to access a replay via our web site at <U>www.davita.com</U>.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>This release also contains forward-looking statements. Factors which could
impact future results include the uncertainties associated with governmental regulation, general economic and other market conditions, and the risk factors set forth in the Company&#146;s SEC filings, including its Form 10-Q for the quarter ended
March 31, 2004. The forward-looking statements should be considered in light of these risks and uncertainties. These risks include those relating to: </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>the concentration of profits generated from PPO and private indemnity patients and from the administration of pharmaceuticals, </I></FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>possible reductions in private and government reimbursement rates, </I></FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>changes in pharmaceutical practice patterns or reimbursement policies, </I></FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>the Company&#146;s ability to maintain contracts with physician medical directors, and </I></FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>legal compliance risks, such as the ongoing review by the U.S. Attorney&#146;s Office and HHS Office of the Inspector General in Philadelphia. </I></FONT></TD></TR></TABLE>
</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g76900clip_image002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g76900clip_image002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!:`2P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBLW4M3D@E6RL(!=7\@RL9.$C']^0]E_4]J:5Q-V)-6UG3]#LS=
MZC<I!'G`SR7/HHZD^PKF7U7QCXCQ_8E@FC63'BZOQF5QZB/M^-;&G>&88;P:
MIJ<G]HZH?^6\@^6+VC7H@_7U-;E7>,=M2;.6^APW_"M#?G?K_B/4]18CE!)L
M3\N:F'PH\*!<?9[@G'WC<-FNSHI^VGW%[.'8\^N/A/;VV9=!UN_TZ8<C+[E)
M_#!K*E\3>-O`DZ1:]"NIV);"SYZ_1P.#[,*]6J*YMH+RW>WN8DFAD&UT<9!%
M4JS>DU="=)?9T,SP[XITKQ/:^=IT^74?O(7XDC^H_J.*V*\3\4^&]0^'NMPZ
MSHDTBVC-B-S\WED]4;U![?XUZ=X1\4VOBO21=0CRYX\+<0Y^XW^![&BI227/
M'84*C;Y9;F]1116!L%%%%`!1110`4444`%%9]KJ(DOKNVE90(3E6Z<=_RIMG
M?F^U.3R23;PIMSV9B>OZ5S+%4W9)ZMV^[<V=&:O?HKFE111728A1110`4444
M`%%%%`!1110`4444`%(>E+10!S.IV^NZ=I]U?R^)PL=O&TA'V"/H!G'6O+O^
M%J>+3_R]P9]/LZUWWQ9U7[#X3^QJV)+^41X_V!\S?R`_&O+/!NE?VSXLT^S*
M[H_-$D@_V5^8_P`L?C7H4(Q<'.:..K)J:C%GM%GIWB>>Q@FG\2"*62-6>,6,
M9"L1DCKVI9])\5@9M_%$.1VETY<'\0:Z.BN+G?E]R.KE1PU[XOU_PI-&/$VF
M17%DYVB^L,X!_P!I6Z'\1[9KI]"N=,OM/%[I4RSQ3G<\N<LS=]W?/L>E3ZGI
M\&JZ9<6%RH:*XC*,#[]_P/->'>"O$=QX1\3&WGD(LY)?)ND)X!!QO^H/Z9K:
M,%5BVM&OQ,I2=.2OLSWRBD!!&0<@TM<QN%%%%`!1110!4U73+;6-,GT^[3?#
M.A5O4>A'N.M>&:7?7WP[\:R1399(7\JX4#B6(\AA^&"*]^KR[XQ:$&AM==B4
M!D(@GP.H.2I_/(_$5U8>2OR/9G/7CIS+='IL,T=Q`DT3AXY%#(PZ$'D&I*\_
M^$FO_P!H:')I,SYFL#\F>IB/3\CD?E7H%83@X2<6;0ES13"BBBH*"BBB@!&&
MY2,D9[@\UDZ@FK00N\%VKQJ,G*@,!]>E:]9.K237C_V;:#+-@RMV0>AKBQJ7
MLF[N_2SLVSHP]^?I;K<Y=G+,69B2W))/6NIT&2S-IY=L3O',@;[Q/K]*GLM*
MMK.#8465CRSLH.:5M,@2X2XME$,BGG;P&'<$5YN"P%?#255V;>ZZKT?<Z\1B
MJ=9.&J+M%%0W5U;V5M)<W4R0PQ#<\CG`4>]>^>8345RUS\1/#L<\5K971U"Z
MF<1QPVRELL3@?,>!^==15.+CNA*2>PM%%%2,****`"BBB@`HHHH`***CGF2W
M@DGE;;'&I=CZ`#)H`\6^+>J_;?%:V2-E+&(*1_MM\Q_3;6I\&=*WW=_JSKQ&
MH@C)]3RWZ`?G7G>J7[ZIJMWJ$GWKF5I#[9/`_*O>/A]I/]C^#;*)EQ+.OGR?
M5N1^F!^%>C6_=T5$X:7OU7(Z6BBBO..X0D`$DX`KYAU&5;C4KN9>%DF=A]"Q
M-?1'BO4?[*\+:C>YPT<#!/\`>(P/U(KYOZ"N_!K1LX\2]D?1_A*\:_\`">EW
M3DEGMDW$]R!@_P`JV*QO!]JUEX0TJW<$,MLA(/8D9_K5K6-:T_0;!KW4;A88
M5X&>2Q]`.YKCDKS:1U1=HILOTA('4@5Y-/X^\1^,-872/#,7V&.0_P"M(S(%
M[LQZ*/IS[UUME\.])$8?69;G6;H_?FNIG(S[+G`JY4N3XV0JG-\*.L!!Z'-+
M7(W_`(,&EQ-?>$Y9=/O8AO%N)&:&XQ_"RDD<XZBO/_$OQ,UB]U&-])NY;&!8
M5#Q!1_K.K=1V/'X4X474?NL)5>3XD>W5E^)=+&L^';[3R,M-"P3V8<K^H%9O
M@"35;GPM!>ZO=O<SW3&12X`VIT4<#VS^-=-6;3A+T+7O1]3Y]\`:NVB>,;-W
M.V.=OL\P/8,<?HV*^@J^<_&-@=*\8:E;H-H$YD3V#?,/YU[UX=U(:QX>L-0!
MR9X%+?[V,-^H-=6*5[374Y\.[7BS2HHHKB.H***Y?5?$%Q?ZJ?#WAYE>[Q_I
M=W]Y+-?ZOZ#\ZJ,7(3:1O+?Q2:@UE$&D>-=TK+]V//0$^I]/3\*GCB2($(H&
M3D^YJK8Z7!INF_8K,M&,',I.YV<]7)/5L\Y->>^.Y]7\)Z=;M#XKU">YN9"J
MHZQ@;0/F/"Y[C\ZJ--3E9$RFXQNST[..M+7BG@$ZKXK\70R:GJ-U=6]B//=9
M925+#A1CIUY_"O:Z=6G[-VN*G/G5PKSGXPZU]FT>VTB-\27;[Y`/[B_XMC\J
MZ_5M'OM1N4EMM=O-/14VF.!4(8YZG<":\&\4W\M]X@N3)?S7R0,88YYL;F53
M[`#&<UKAJ:E.]]C.O-J-NYTGPET4W_B5]1D7,-@F02.LC<#],G\J]LKSOP7X
M*O[?PY;W$6O7NGO>*)I(H43'/3[P)Z8KI]/T#4+.]CN)_$E_>1IG,,JQA6X[
MX7-*O)3FW<=%.,4K&[13))(X8FEE=41`69F.``.YKS+Q'\5Y)+K^SO"\`F=F
MV+<NN=S'@;%[_4_E64*<INR-)SC!:GIY..M`8'H0:X;1O`=S?PK=^,-1NM1N
M'&?LIG(BB]B%(R?T^M:4WP^T';OT^*;3+E>4N+29E93^>#]#0XP3M<$Y/6QU
M%%>1^*O'>O:59)H;W!AU>UG*SW42C$L>`489'&[//TK5^%VJ>(-=N+R]U/49
MKBUA41HC``%SR3P.P_G5NA)0YVR%53ERH]'HHHK`V"N3^)>J_P!F>"[I5;$M
MV1;I_P`"^]_XZ#765Y!\9-5\[5;+2D;Y;>,RN/\`:;@?H/UK:A'FJ)&5:7+!
MG#Z!IK:QKUCIRCBXF56]EZM^@-?2J*J($4`*HP`.PKQSX/:5]I\07.I.N4LX
M=JG_`&WX_D#^=>RUKBY7G;L9X>-HW[A114-W=06-I+=7,@CAA0N[GH`*Y#I/
M.OC'K0BL+318V^>=O.E`_NKP!^)_]!KS?PWH\FO>(+/34!Q+(/,(_A0<L?RI
M?$NMR^(M?NM3DW!96Q$A_@0<*/R_4UZK\,/"#Z+I[:K?1;;V\4;$8<Q1]<>Q
M/4_A7IW]A2\S@M[6IY';S306-F\TC"."",LQ[*H'^%?/?BWQ3=>*=6>ZE9DM
MD)%O`3Q&OK]3W->N?%"YDM_`MX(SCS72-C_LEAFO&O#.F?VQXDT_3R,I-.N_
M_='+?H#6>%BE%S9>(DVU!'L/PT\-+H?AU+N9,7E^!+(2.53^%?RY^IKLJ0`*
M``,`<`"EKBG)RDY,ZHQ459&9XBU:/0]`O-2D/^IB)0?WF/"C\R*^>M&TZ77-
M<M;!,E[J8!B.PSEC^`R:]$^,>N?\>FAQ/_T\3@'\%'\S^55?@[HHGU&[UF5?
MEME\F+/]YOO'\!Q_P*NVE^[HN?<Y:G[RHHGK4$,=M;QP0J%CB4(BCL`,`5)1
M17`=AXK\8+/R/%<%R!Q<VJY^JDC^6*ZWX0:A]I\+2V;'+6=P0/\`=;YA^N:S
M/C3;Y@TJZ`/#R1DYXY`(_D:SO@U>^5KE_9%L">W#@>I4_P"#5WM<V&]#C7NU
MSV&BD9@BEF("@9))X%>4^,/'EWKUZ/#GA;S&\U_+>>,X,WJ%/9?5OZ5R4Z;F
M[(Z9S4%J:_B/QE>:OJB^&?"+B2[D)6XO!]V%1UP?;N?RYKJ?#?AVS\,Z2EC:
MC<Q^::9OO2OW8U3\&>$+;PGI?EC$MY,`;B;'4_W1_LC_`.O71TYR7PQV_,4(
MOXI;A7@WQ,UG^UO&$\:-F&Q'V=.>I'+'\SC\*]E\2:NFA>'[W47.##$=@]7/
M"C\R*^>])L)]=URVL06:2[F`=N_)RS?EDUT86.\WT,<1+:*/8/A1HHT[PL+Y
MUQ-J#^8<CD(.%'\S^-=Q4=O!':VT5O"H2.)`B*.P`P*DKEG+GDY'1&/+%(P?
M&VM?V#X4O;Q'VS,GE0_[[<#\N3^%>&>%]';7?$EEIVTLDL@,OL@Y8_D*[/XQ
M:UY^I6FC1M\MLOG2_P"\W0?@/YU<^#>BXCO=;E3[Q\B$GT'+'^0_`UVT_P!U
M1<NK.6?[RJH]CU!55$"J`%48`'84ZBH+V9K>QN)E`+1Q,PSZ@9KSSL/(?BAX
MQDU#4)-"L9<6=L<3E3_K9.X^@_G5KX0^'$N+B;7[E-RP'RK8$?Q8^9OP!`_$
MUYH\CRNTKDL[DL3ZDU]'^%M*71?#-A8!<-'"#)[N>6_4FO1K6I4E!=3BI7J5
M.9FO2$A5+,0`!DD]J6N5^(^M_P!C>$;D1R;;B[_<1>O/WC^"Y_2N",7*22.R
M3Y5<\:\6ZQ_;WB>^U!>8WDVQ?[B\+^8&?QKV_P`$:+_87A.SM&&)77SIO]]N
M2/PX'X5XQX%T7^W/%EE;,FZ&)O.F';:O./Q.!^-?0]=F*DDE!'+AU=N;"BBB
MN$ZQ"0!D\"OF_P`4ZH=9\3:A?YRDDQ$?^X.%_0"O<G\)K(C(^NZT588(^V=1
M^58O_"HO"_\`T^_]_P#_`.M750J0IMMG/5A.:21-\+-*_L[P=%.ZXDO7:8_[
MO1?T&?QKLZYZ'PA%;PI##K>LQQ1J%1%N\!0.@'%/_P"$6_ZC^M_^!G_UJRFU
M*3E<TBG&*5C8NKNWLK=[BZGC@A099Y&"@?B:\>\;>-;GQA<KH>@PS2VF[G8A
M+W##IQV4?_7KO)OASHEY,LFHSZCJ&WHMU>.X'\JW=-T73-'B\O3K&"U4C!\M
M`"?J>I_&JA*%/7=DRC.>FR.#\$?#$:?+'JFO*KW"$-%:@Y6,^K>I]N@]Z]*H
MHK.=24W>1<(*"LC&\6Z(?$'AF\TY<>:Z;HB>S@Y'ZC'XUY#\-0+/X@VT-XIA
ME42Q['&"'VG@^_6O=ZYWQ!X'T;Q#.+N>.2VO5P5NK9MCY'3/8XK6E548N#V9
M%2G=J2W1T59>O:_9^'[`W-TQ:1SM@@3F29^RJ.]9D?AOQ!'&(AXSO#&./FM(
MBV/]XC.?>KVE^%[#3;HWLCSWU\1C[7>/YD@'HO91]`*SM%;NY=Y/H>$>*VU1
MO$EY)K,?EWLC!W0'(0%054?08%>V>#[&W\-^";07$D<*B+[1/(QP`6Y.3[#`
M_"H/%GP_TSQ5.MW)++:W:J%,L8!#KZ,#UJ&T^'D?EPV^KZW?ZK9P8\NTE;;$
M,=,@?>Q[UT5*L*D$KV,84Y0DWN:/AW7+WQ#>7-[%`L6C*-EK(ZD27#`\N/1>
MPKH*;'&D4:QQHJ(HPJJ,`#T`IU<DFF]#H2LM3@/C%"'\*VTNS)CO%^;^Z"K#
M_"O.O`&I1Z5XSL;B>5(H3O21W8``%3R3]<5ZA\6(V?P/*5&0D\;-[#./ZBO#
M*]'#KFI-,XJ[Y:ESO?''C^Y\23G1]&#BQ9PFY`=]T>PQ_=SV[UW'P_\`!$?A
MJR%Y>(KZG.OSGKY*_P!P?U-9OPV\!_V5&FMZK%_ILBY@B;_E@I[G_:/Z"O1*
MYZM1)>SAL;4X-OGGN%%%%<IT'F_QFO)HM(T^S4XBGG9W]]HX'_CWZ5D_!S2$
MGU*\U>0`FU411CT9NI_(8_&O3-=T#3O$>GFRU*$R1YW*RG#(WJ#VKE]/^%=C
MIL\CVVMZM#'(,.D,PCW#T)`YKKA5C[+DV9SRIR]IS;FYKWB06#C3=-C%[K$_
M$-JI^Y_MR'^%1UYZUJ:;'>1:=`FH3I/=A!YTB)M5F[X%0:1H.F:'"T>GVJQ%
MSF20DL\A]68\FM&N9M6LC9)[L^;?$]U-?>*=3GF!\QKEUVGL`<`?D!7OWAK2
MDT3PY8Z>HYAB&\XQECRQ_,FL7Q#\-M"\07CWK^=:74G+O`P`<^I!!&?RJ:W\
M$@6R6M_KVK7UL@VB!Y]BD>C;0"1^-=-6K&I!).UC"G3E"3>Y)J'B*?4+J32/
M#02YNU^6>[/,-I[D_P`3>BC\:U-*T>+3-*%B99;G=N,TLS%FE9OO$YZ9].E6
M;*QM=.M4M;*WCMX(QA8XUP!4]<[DMD;I=6?.6MZ)-X:\3FQNUVQ),'C=AP\6
M[AORZ_C7T7&Z21J\;!D8`JRG(([8K-UWPYI7B.U%OJ=JLH7[CCAT^A[5CV?@
M[5-*@%KIGBV^AM4X2*:".;8/0$CI[5M4J*K%7=FC*$'3;MJCIKN[M["UDNKN
M9(((EW/(YP%%>(?$75-0UN[M-2EMY(-+D#K8*_!<`C<Y7MG(Q[8KU2+PA!-.
MEQK5]<ZS+&<HMR0(5/J(U`7/US5GQ)X8T[Q1IPL[Y678=T4D9PT9]O\`"E2G
M"G*^XZD93C8XWX-Z0L6F7FL.O[RXD\F,^BKR?S)_2NF_X22;4_$B:5H:Q30V
MK;M0NF!*(/\`GFN.KG]*R-.^&<FGV[6:>*-26QD.9+>'$8?/7GG&>]=?I>E6
M.C6$=CI]NL$$?15[GU)[GWHJRBY.6X4XR45'8S?$/BB/0W6%;9KB78)'^;8D
M2E@BECSU8X&`>]9L7Q*T6&)1JWF6$[#<J%2X=>S*0.0<'K@\&M37_#$.N2QS
MBY>VG0*K$*'25`P<*ZGJ`P!_/UK/3X<Z'-&IU1'U"91M1W8H(T'1$53@*.PY
M^M*/LN7WAOVE]#K****P-0HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`Y
M'XH_\B'>_P"_'_Z&*YKX;_#_`!Y6O:S#SP]K;N.GH[#^0_&N_P!?ABN+*"*:
M-)8VNX=R.H(/SCJ#6I6ZJ.-/E74R<%*=WT"BBBL#4****`"BBB@`HHHH`***
8*`"BBB@`HHHH`****`"BBB@`HHHH`__9
`
end

</TEXT>
</DOCUMENT>
</SUBMISSION>
